论文部分内容阅读
最近证明WFA+-M2BP是一种独特的纤维化相关的早期活性标志物,来自日本长崎医疗中心的Yamasaki K等通过评估WFA+-M2BP的活性来预测丙型肝炎患者肝细胞癌(HCC)的发生。共有707名无其他潜在干扰因素且被确诊为慢性HCV感染的患者参与评估,以确定WFA+-M2BP对HCC发生的预测能力;评估的因素包括年龄、性别、病毒载量、基因分型、纤维化阶段、ALT、AST、胆红素、白蛋白、血小板计数、甲胎蛋白、WFA+-M2BP及
Recently, WFA + -M2BP has been shown to be a unique early marker of fibrosis-related activity. Yamasaki K from Nagasaki Medical Center in Japan predicted the occurrence of hepatocellular carcinoma (HCC) in hepatitis C patients by assessing the activity of WFA + -M2BP . A total of 707 patients without other potential disturbing factors who were diagnosed with chronic HCV infection were included in the assessment to determine the ability of WFA + -M2BP to predict HCC occurrence; factors assessed included age, gender, viral load, genotyping, fibrosis Stage, ALT, AST, bilirubin, albumin, platelet count, alpha-fetoprotein, WFA + -M2BP and